Abstract
Obesity is a metabolic disease characterized by a chronic subclinical inflammatory response associated with an imbalance/dysregulation of cellular homeostasis in response to excessive nutrient intake and accumulation. CD4+ T-lymphocytes form different populations, Th1, Th2, Th9, Th17, Th22, and Treg cells, which have phenotypic and functional differences. Despite the active study of Th17 cells in severe disorders, their role in metabolic disorders, particularly in obesity, is not well understood. Th17 lymphocytes, depending on the microenvironment, can form pathogenic and nonpathogenic subpopulations. Systemic inflammation induces the reprogramming of the transcriptome of normal Th17 cells formed in epithelial tissues, which acquire new properties. A zone of overlapping states exists between IL-17A-producing cells, which does not allow a clear boundary between non-pathogenic Th17 and pathogenic Th17 lymphocytes. We assume that in obesity, the pool of inflammatory pathogenic Th17 cells with cytotoxic potential is a fraction of terminally differentiated memory lymphocytes which is responsible for developing autoimmune reactions.
Keywords: Obesity, type 2 diabetes mellitus, non-pathogenic Th17 cells, pathogenic Th17 cells, plasticity, CD4+CD28null cells, inflammation, autoimmune disorder.
Animated Abstract
Current Pharmaceutical Design
Title:The Pathogenic Subpopulation of Th17 Cells in Obesity
Volume: 27 Issue: 37
Author(s): Natalia Todosenko, Maria Vulf*, Kristina Yurova, Daria Skuratovskaia, Olga Khaziakhmatova, Natalia Gazatova, Olga Melashchenko, Olga Urazova and Larisa Litvinova
Affiliation:
- Center for Immunology and Cellular Biotechnology, Immanuel Kant Baltic Federal University, Kaliningrad,Russian Federation
Keywords: Obesity, type 2 diabetes mellitus, non-pathogenic Th17 cells, pathogenic Th17 cells, plasticity, CD4+CD28null cells, inflammation, autoimmune disorder.
Abstract: Obesity is a metabolic disease characterized by a chronic subclinical inflammatory response associated with an imbalance/dysregulation of cellular homeostasis in response to excessive nutrient intake and accumulation. CD4+ T-lymphocytes form different populations, Th1, Th2, Th9, Th17, Th22, and Treg cells, which have phenotypic and functional differences. Despite the active study of Th17 cells in severe disorders, their role in metabolic disorders, particularly in obesity, is not well understood. Th17 lymphocytes, depending on the microenvironment, can form pathogenic and nonpathogenic subpopulations. Systemic inflammation induces the reprogramming of the transcriptome of normal Th17 cells formed in epithelial tissues, which acquire new properties. A zone of overlapping states exists between IL-17A-producing cells, which does not allow a clear boundary between non-pathogenic Th17 and pathogenic Th17 lymphocytes. We assume that in obesity, the pool of inflammatory pathogenic Th17 cells with cytotoxic potential is a fraction of terminally differentiated memory lymphocytes which is responsible for developing autoimmune reactions.
Export Options
About this article
Cite this article as:
Todosenko Natalia , Vulf Maria *, Yurova Kristina, Skuratovskaia Daria , Khaziakhmatova Olga , Gazatova Natalia , Melashchenko Olga , Urazova Olga and Litvinova Larisa, The Pathogenic Subpopulation of Th17 Cells in Obesity, Current Pharmaceutical Design 2021; 27 (37) . https://dx.doi.org/10.2174/1381612826666210101154913
DOI https://dx.doi.org/10.2174/1381612826666210101154913 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immunomodulatory Properties of Farnesoids: The New Steroids?
Current Medicinal Chemistry Reactive Oxygen Species in Myocardial Reperfusion Injury: From Physiopathology to Therapeutic Approaches
Current Pharmaceutical Biotechnology An Update on the Association of Protein Kinases with Cardiovascular Diseases
Current Pharmaceutical Design Impact of Omega-3 and Trans Fatty Acids on Vascular Remodeling:Opposing Roles in Cardiovascular Health
Current Enzyme Inhibition Endothelial Dysfunction in Cardiac Allograft Vasculopathy: Potential Pharmacological Interventions
Current Vascular Pharmacology Patent Selections
Recent Patents on Cardiovascular Drug Discovery Epigenetic Modulation of Myocardial Angiogenic Balance: An Emerging Therapeutic Perspective for Adult Failing Heart
Current Angiogenesis (Discontinued) Nitric Oxide and Protection against Cardiac Ischemia
Current Pharmaceutical Design Inflammatory Mediators and the Failing Heart: A Translational Approach
Current Molecular Medicine Pexelizumab and its Role in the Treatment of Myocardial Infarction and in Coronary Artery Bypass Graft Surgery: A Review
Recent Patents on Cardiovascular Drug Discovery Protein Kinase C Isozymes: Memory Therapeutic Potential
Current Drug Targets - CNS & Neurological Disorders Nephroangiosclerosis and Its Pharmacological Approach
Current Vascular Pharmacology Role of Nuclear Steroid Receptors in Apoptosis
Current Medicinal Chemistry Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Current Drug Metabolism Susceptibility of Periodontopathogenic and Cariogenic Bacteria to Defensins and Potential Therapeutic Use of Defensins in Oral Diseases
Current Pharmaceutical Design Banaba Restricts Brain Damage: Neuroprotective Role in Cerebral Ischemiareperfusion Injury
Current Indian Science Computational and Experimental Progress on the Structure and Chemical Reactivity of Procyanidins: Their Potential as Metalloproteinases Inhibitors
Current Organic Chemistry Editorial (Thematic Issue: Cardio-Metabolic Complications: Current Perspective and Future Developments)
Current Pharmaceutical Design Unveiling the Molecular Mechanism of Diosmetin and its Impact on Multifaceted Cellular Signaling Pathways
Protein & Peptide Letters Heterocyclic Compounds as Anti-Inflammatory Agents
Current Bioactive Compounds